EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.

Dynamic Global Events (“DGE”) is proud to announce the 6th Clinical Trial Agreements Summit taking place August 21-22 in Philadelphia. This event wil ...

In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide, according to the World ...

Analysts are intrested in these 5 stocks: ( ($RNA) ), ( ($BBIO) ), ( ($COTY) ), ( ($SAGE) ) and ( ($ALKS) ). Here is a ...

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $42.00. The company’s shares ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF – Research Report) and Alkermes (ALKS – Research Report). Confident I ...

Alkermes ALKS underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings ...

UBS upgraded Alkermes (NASDAQ: ALKS) from Neutral to Buy on Tuesday, raising its price target to $42.00 from $33.00. The upgrade reflects UBS’s growing confidence in the company’s orexin ...

Alkermes has a one year low of $22.90 and a one year high of $36.45. The stock has a market cap of $5.74 billion, a PE ratio of 16.28, a P/E/G ratio of 2.21 and a beta of 0.49.